Shanghai Serum Bio-Technology Co., Ltd. Class A

As of June 30, 2026, Shanghai Serum Bio-Technology Co., Ltd. Class A carries a market capitalization of 5.28B, placing it among publicly traded companies globally. Its enterprise value stands at 4.54B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Shanghai Serum Bio-Technology Co., Ltd. Class A has 108.22M shares outstanding.

As of June 30, 2026, Shanghai Serum Bio-Technology Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 88.73. The price-to-sales ratio is 23.21, and the price-to-book ratio stands at 4.72.

As of June 30, 2026, Shanghai Serum Bio-Technology Co., Ltd. Class A trades at an EV/EBITDA multiple of 71.35 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 22.67 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 71.35 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 4.54B versus a market cap of 5.28B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Shanghai Serum Bio-Technology Co., Ltd. Class A maintains a current ratio of 16.08, meaning it holds 16.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.44, indicating conservative leverage, while an interest coverage ratio of 339.80 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Shanghai Serum Bio-Technology Co., Ltd. Class A posted a return on equity (ROE) of 4.73, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.73 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.56, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.72, useful for judging operating efficiency across full business cycles. The company generates approximately 609,349.06 in revenue per employee across its workforce of 329.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.00 indicates how many times Shanghai Serum Bio-Technology Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Shanghai Serum Bio-Technology Co., Ltd. Class A recorded 10.50M in income tax expense. That works out to an effective tax rate of 16.68, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 62.94M, leaving 52.45M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Shanghai Serum Bio-Technology Co., Ltd. Class A's stock has gained approximately 31.18% over the past 52 weeks. The 50-day moving average sits at 34.54, while the 200-day moving average is 32.42.

Over the twelve months ended June 30, 2026, Shanghai Serum Bio-Technology Co., Ltd. Class A generated 200.48M in revenue and converted that into 52.45M in net income, yielding earnings per share of 0.55. EBITDA reached 63.70M, while operating income came in at 59.09M.

As of June 30, 2026, Shanghai Serum Bio-Technology Co., Ltd. Class A holds 742.45M in cash and equivalents against 4.88M in total debt, resulting in a net debt position of -188.86M. Total book value stands at 1.12B, with working capital of 844.70M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shanghai Serum Bio-Technology Co., Ltd. Class A posted a gross margin of 77.97, reflecting its pricing power and cost economics. The operating margin of 29.47 and net profit margin of 26.16 provide insight into operational efficiency.

As of June 30, 2026, Shanghai Serum Bio-Technology Co., Ltd. Class A has an Altman Z-Score of 50.90, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.